<DOC>
	<DOCNO>NCT02561338</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy population PK HMS5552 type 2 diabetic adult subject , 5 group ,4 group receive HMS5552 , 1 receive placebo .</brief_summary>
	<brief_title>A Multi-center 12-week Study HMS5552 T2DM</brief_title>
	<detailed_description>Glucokinase ( GK , also call hexokinase IV D ) phosphosphorylate glucose glucose-6-phosphate ( G-6-P ) pancreatic β-cells liver cell , represent first step glucose metabolism . GK also act glucose sensor exerts key role maintain glucose homeostasis . HMS5552 4th-generation GK agonist activator ( GKA ) , originally license Roche subsequently develop Hua Medicine . HMS5552 show activate GK pancreatic beta cell , liver intestinal epithelial cell . It regulate systemic blood glucose variety mechanism include directly enhance insulin release ( pancreas ) , inhibit production endogenous glucose ( liver ) indirectly promote GLP-1 release ( enteroendocrine L-cells ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Male &amp; female , 40~75 year old 2 . T2DM patients，antihyperglycemic drugnaïve diet &amp; exercise least 3 month , glucose control Metformin αglucosidase inhibitor alone 3 . HbA1c 7.5~10.5 % screen prerandomization 4 . Fasting plasma glucose ( FPG ) 7.0~11.1mM ( local lab ) screening , 7.0~13.3mM ( central lab ) prerandomization 5 . BMI : 19~30kg/m2 &amp; TG &lt; 5.5mM 1 . T1D，secondary DM , preDM 2. kidney disease eGFR MDRD &lt; 60ml/min/1.73m2 3. unstable CVDs， 4. liver diseases， 5. mental CNS diseases，</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>GKA , T2DM , HMS5552</keyword>
</DOC>